Novo Nordisk's pricing approaches within the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of price tag gouging, mentioning the stark contrast between U.S. price ranges and those in Europe and copyright. In Oct 2024, Novo Nordisk released